Overview
Germany specialty chemicals firm's preliminary Q1 sales revenue fell 13% yr/yr
Preliminary Q1 EBITDA slightly below prior year, but EPS doubled to EUR 0.10
Company cites improved earnings below EBITDA due to lower depreciation and input costs
Outlook
H&R maintains 2026 full-year EBITDA guidance of EUR 85 mln to EUR 100 mln
Company says ongoing supply disruptions in the Persian Gulf may affect earnings stability
H&R must pass on higher raw material costs to customer industries in the short term
Result Drivers
CHEMPHARM REFINING SEGMENT - Operating profit in the ChemPharm Refining segment rose despite lower revenue
SUPPLY DISRUPTIONS AND RAW MATERIAL COSTS - Demand picked up at the end of Q1 due to the war in the Persian Gulf and closure of the Strait of Hormuz, but raw material costs rose sharply
IMPROVED CASH FLOW - Operating and free cash flow improved, mainly due to lower input costs and reduced net working capital needs before the Strait of Hormuz closure
Company press release: ID:nEQ82cp9ya
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales Revenue
EUR 300.20 mln
Q1 EPS
EUR 0.10
Q1 EBIT
EUR 9.50 mln
Q1 EBITDA
EUR 21.90 mln
Q1 Pretax Profit
EUR 6.70 mln
Analyst Coverage
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the commodity chemicals peer group is "buy."
Wall Street's median 12-month price target for H&R GmbH & Co KgaA is €4.00, about 12.5% below its April 29 closing price of €4.57
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 22 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)